TVGN earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Hold, P/E -0.73. Updated 2026-07-23.
Tevogen Bio Holdings (TVGN) Research Hub
Tevogen Bio Holdings (TVGN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 7.36 USD (+0.27%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.73, market cap 0.02B. This hub links to the full technical, earnings and options research available for TVGN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 7.36 USD (+0.27%) |
| 52-week range | 3.64 USD – 10.42 USD |
| Trend regime | Range |
| 14-day RSI | 73.1 (Overbought) |
| Trailing P/E | -0.73 |
| Market cap | 0.02B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for TVGN
Covered Call on TVGN: how it works, illustrative setup around the real 7.36 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TVGN: how it works, illustrative setup around the real 7.36 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TVGN: how it works, illustrative setup around the real 7.36 USD price, max profit/loss, breakeven and when to use it. Educational.
TVGN technical analysis: range, last 7.36 USD, RSI 73.1, 52w range 3.64 USD–10.42 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is TVGN in?
Tevogen Bio Holdings (TVGN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is TVGN in an uptrend or downtrend?
As of 2026-09-11, TVGN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TVGN's trailing P/E ratio?
TVGN's trailing P/E is -0.73, with a market cap of 0.02B. See the earnings research page for full valuation detail.
When does TVGN next report earnings?
TVGN is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -2.535 USD.